HWI Group
HWI Group is a family-owned German CDMO and pharmaceutical services provider delivering GMP/FDA-certified laboratory analytics, drug development, QP batch release, regulatory, and pharmacovigilance services across three German sites to pharmaceutical and biotechnology clients.
- Company typePrivate
- Founded1992
- HeadquartersRülzheim, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What HWI Group does
HWI Group (legal entity: HWI pharma services GmbH) is a family-owned, independent German pharmaceutical services provider founded circa 1992 and headquartered in Rülzheim, Rhineland-Palatinate. The company operates a full-service Contract Development and Manufacturing Organization (CDMO) and analytical services platform across three German sites — Rülzheim (headquarters with GMP/FDA-certified laboratories), Appenweier (GMP manufacturing for human and veterinary products), and Frankfurt am Main (opened in 2020 for development services). The company employs 51–100 people and serves mid-to-large pharmaceutical and biotechnology clients primarily in the DACH region with project-based, quote-priced service contracts.
The service portfolio spans five integrated pillars: (1) Laboratory Services including analytical method development and validation, biologics characterization using SCIEX ZenoTOF 7600 high-resolution mass spectrometry, impurity trace analysis, ICH stability testing, and a proprietary catalog of pharmaceutical reference standards; (2) Drug Development (CDMO) covering formulation development, small-batch manufacturing (up to 100 kg), clinical trial product manufacturing, sterile powder filling, and product lifecycle management, supported by a 360° cleanroom with OEB5 containment for high-potency active ingredients; (3) QP Services including Qualified Person batch release for investigational and marketed products, GMP/GDP audits, and EU import batch certification; (4) Regulatory Services from IMPD/IB preparation through marketing authorization and variation maintenance; and (5) Pharmacovigilance Services covering GVP-compliant case processing, PV audits, periodic reporting, signal management, and EU-QPPV functions. Differentiated technology assets include charged aerosol detection (Corona VEO RS) for non-chromophoric compound quantification and electron-activated dissociation mass spectrometry for labile PTM preservation on biologics.
The business operates a B2B enterprise field sales model led by Head of Sales Lilia Selinger, with multi-year project contracts, no public pricing, and direct inquiry routing by service line. The company is led by Managing Directors Dr. Frank Böttcher and Dr. Stefan Wissel (appointed 2021) with no disclosed external investors, parent company, or funding rounds, maintaining its independent family-owned status across three decades. HWI maintains a strategic research partnership with the University of Bonn's Institute of Biochemistry and Molecular Biology for non-clinical development support and publishes thought-leadership content via Pharmind, Cleanroom&Processes, blog, and YouTube channels.
HWI Group firmographics
Firmographics- Name
- HWI Group
- Legal name
- HWI pharma services GmbH
- Website
- https://hwi-group.de
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- HWI Group is a family-owned German CDMO and pharmaceutical services provider delivering GMP/FDA-certified laboratory analytics, drug development, QP batch release, regulatory, and pharmacovigilance services across three German sites to pharmaceutical and biotechnology clients.
- Ownership category
- akta.pro rank
HWI Group industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule API & Intermediates CDMO (HLAGABAA), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where HWI Group is headquartered
LocationHeadquarters
- HQ city
- Rülzheim
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
HWI Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Services: Analytical testing, method development and validation, stability studies, quality control, reference standards for pharma/biotech clients. Services rendered under GMP/FDA certification.
- Drug Development (CDMO): Formulation development, clinical trial manufacturing, small batch production, sterile powder filling, product lifecycle management for pharmaceutical companies.
- QP Services: Qualified Person batch release services, quality management consulting, GMP/GDP audit preparation, regulatory compliance support.
- Pharmacovigilance Services: GVP-compliant pharmacovigilance services, PV audits, periodic reports, risk management, signal management, EU-QPPV services for medicinal products and medical devices.
- Regulatory Services: Regulatory strategy, IMPD/IB preparation, marketing authorization dossier support, variation implementation, registration maintenance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based pharmaceutical services pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
HWI Group product offering
Product offeringCore offering
HWI Group is a contract development and manufacturing organization (CDMO) that delivers pharmaceutical services across the drug lifecycle, including GMP- and FDA-certified laboratory analytics, formulation and process development, small-batch manufacturing, clinical trial supplies, Qualified Person batch release, regulatory affairs, and pharmacovigilance. The company operates three GMP-certified sites in Germany (Rülzheim, Frankfurt, Appenweier) serving pharma and biotech clients with active ingredients, medicinal products, and associated products.
Product overview
HWI Group is a CDMO (Contract Development and Manufacturing Organization) providing integrated pharmaceutical services for the pharma and biotech industries. The portfolio consists of five interconnected service pillars: (1) Laboratory Services covering analytical method development, validation, biologics analytics, impurity/trace analysis, stability testing, and reference standards; (2) Drug Development encompassing formulation development, small batch manufacturing, clinical trial manufacturing, sterile powder filling, and product lifecycle management; (3) QP Services including batch release, external Qualified Person services, and GMP/GDP audits; (4) Regulatory Services for development support through marketing authorisation; and (5) Pharmacovigilance Services including GVP audits. All laboratory and manufacturing operations are GMP- and FDA-certified across three German sites in Rülzheim, Frankfurt, and Appenweier.
Differentiator
Problem solved
Functional benefit
Products and services
- Laboratory Services Comprehensive GMP- and FDA-certified pharmaceutical analytics and quality control services including method development, validation, batch release testing, and stability studies for active ingredients, excipients, medicinal products, and drug-related products. Targets pharma and biotech companies requiring regulatory-compliant analytical work.
- Development and Validation Analytical method development and validation for identity testing, assay, purity testing, and in vitro dissolution for active ingredients, excipients, intermediates, ready-to-use products, and medical devices following international regulatory requirements.
- Analytics of Biologics Specialized biopharmaceutical analytics including characterization of proteins, peptides, nucleic acids, lipids, and glycans using advanced mass spectrometry platforms for biologics and biosimilar developers.
- Impurities Analysis Method development and validation for determination of synthesis by-products and degradation products, with specialization in impurity trace analysis for pharmaceutical clients.
- Stability Testing Complete stability testing services including storage, analytical testing, and stability report preparation for ICH studies and follow-up studies in GMP- and FDA-certified facilities.
- Reference Standards Preparation, purification, and qualification of pharmaceutical reference standards including primary and working standards, with 30 years of expertise in this domain.
- Drug Development (CDMO) Contract development and manufacturing organization offering galenic and analytical development for solid, semi-solid, and liquid dosage forms along with process development and scale-up services for pharmaceutical companies.
- Small Batches Manufacturing Production of small market batches under GMP conditions for non-sterile solutions, micro- and nanosuspensions up to 100 kg batch size, and oral solid dosage forms up to 75 kg.
- Clinical Trial Manufacturing Manufacturing, packaging, approval testing, QP batch release, and distribution of clinical investigational medicinal products for clinical studies conducted by pharmaceutical and biotech sponsors.
- Sterile Powder Filling Sterile powder filling services for pharmaceutical products using state-of-the-art technological equipment enabling processing of high-potency active ingredients.
- Product Lifecycle Management Services for adapting or optimizing already marketed medicinal products including change management, process and product optimization, upscaling, production validation, and method transfer.
- QP Services Qualified Person services including batch release of investigational and marketed medicinal products, external QP function, supplier qualification, and GMP/GDP audit implementation.
- Batch Release QP batch release services for active ingredients, medicinal products, and drug-related medical devices, including EU batch release for import of medicinal products into the EU.
- Regulatory Services Regulatory support for product development from IMPD and IB preparation through marketing authorisation and beyond, including maintenance of registration dossiers and implementation of variations.
- Pharmacovigilance Services Comprehensive pharmacovigilance support based on GVP recommendations including literature research, case processing, PV audits, periodic reports, signal management, and EU-QPPV services for medicinal products and medical devices.
- GVP Audits Good Pharmacovigilance Practice audits for pharmacovigilance systems including structured audit planning, independence and capability assessment for pharma and biotech clients.
Quantifiable outcome
- Detection of non-chromophoric compounds not visible to UV/VIS detectors
- +1 more outcomes
Companies that use HWI Group
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
HWI Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature5 records
HWI Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institute of Biochemistry and Molecular Biology, University of BonncoreCollaboration with Prof. Dr. Häberlein's institute for non-clinical development support. HWI produces formulations for preclinical studies at small scale under GMP conditions while the institute provides consultation and support in preclinical strategy, efficacy and tolerability studies, and mechanism of action elucidation in cell cultures or animals.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
HWI Group competitors and assessment
Company assessmentOthers
Direct peers
- Aenova Group: German-headquartered CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing across multiple sites in Germany, Italy, Switzerland, and the U.S. Closely comparable as a mid-sized European CDMO serving pharma with GMP-certified manufacturing and development services, though at larger scale.
- Recipharm: Sweden-headquartered CDMO with broad sterile and solid-dose manufacturing services across Europe, serving pharma and biotech with GMP-certified facilities. Comparable as a European mid-to-large CDMO offering formulation development, manufacturing, and analytical services, though materially larger than HWI.
- Rottendorf Pharma: German family-owned CDMO specializing in solid oral dosage forms (tablets, capsules), small-to-mid batch GMP manufacturing, and analytical services. Closely comparable given similar German private ownership, mid-tier scale, and focus on small-batch GMP solid-dose development and manufacturing.
- Diapharm: German pharmaceutical services provider offering regulatory affairs, QP services, pharmacovigilance, GMP/GDP auditing, and CDMO support. Directly comparable across HWI's QP services, regulatory services, and pharmacovigilance pillars, with similar mid-sized German footprint.
- Protagen Protein Services: German-based bioanalytical CRO specializing in characterization of biologics, biosimilars, and gene therapy products using advanced mass spectrometry. Closely comparable to HWI's biologics analytics service pillar (proteins, peptides, mAbs, glycans) with similar GMP-adjacent analytical expertise.
- PharmaZell (formerly Euticals): German-headquartered CDMO focused on API manufacturing, process development, and small-batch production with GMP/FDA facilities. Comparable as a European mid-sized CDMO offering API and intermediates development plus specialty manufacturing, overlapping with HWI's API characterization and small-batch drug product work.
Broad incumbents
- Cambrex: U.S./European CDMO offering API development, drug product manufacturing, and analytical services across multiple sites. Comparable as a broader incumbent in small-molecule CDMO with overlapping capabilities in API characterization, method development, and small-batch manufacturing, though at significantly larger scale.
- Eurofins Discovery: European-headquartered bioanalytical and contract research network offering pharmaceutical analysis, stability testing, and method development across global GMP-certified labs. Comparable as a broader analytical services incumbent overlapping with HWI's lab services (impurity analysis, stability, reference standards, method validation).
- Vetter Pharma: German-headquartered global CDMO specializing in aseptic fill-finish, sterile manufacturing, and complex injectable delivery. Comparable as a major German CDMO serving pharma with GMP/FDA-certified manufacturing, though focused on sterile injectables rather than HWI's small-batch solid/liquid/semi-solid scope.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
HWI Group social profiles
Digital presenceHWI Group compliance and trust
Trust signalCompliance8 records
HWI Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
HWI Group leadership team
Management profileNumber of profiles
Profiles6 records
HWI Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HWI Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HWI Group
What does HWI Group do?
HWI Group is a contract development and manufacturing organization (CDMO) that delivers pharmaceutical services across the drug lifecycle, including GMP- and FDA-certified laboratory analytics, formulation and process development, small-batch manufacturing, clinical trial supplies, Qualified Person batch release, regulatory affairs, and pharmacovigilance. The company operates three GMP-certified sites in Germany (Rülzheim, Frankfurt, Appenweier) serving pharma and biotech clients with active ingredients, medicinal products, and associated products.
Is HWI Group a public or private company?
HWI Group is a private company. It is classified as family owned and is currently operating.
When was HWI Group founded?
HWI Group was founded in 1992. It employs 51 to 100 people.
Where is HWI Group based?
HWI Group is headquartered in Rülzheim, Germany, in the Europe region.
How does HWI Group make money?
Five revenue lines are on record. Laboratory Services are the primary driver. The others are drug Development (CDMO), QP Services, pharmacovigilance Services and regulatory Services.
Who are HWI Group's main competitors?
NextPharma is listed as an others. Direct peers are Aenova Group, Recipharm, Rottendorf Pharma, Diapharm, Protagen Protein Services and PharmaZell (formerly Euticals). Broad incumbents are Cambrex, Eurofins Discovery and Vetter Pharma.
Does HWI Group have an API?
No public API is recorded for HWI Group.
What industry is HWI Group in?
HWI Group's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 8731.